CTOs on the Move


 
XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xoma.com
  • 2910 7th St Ste 100
    Berkeley, CA USA 94710
  • Phone: 510.204.7270

Executives

Name Title Contact Details

Funding

XOMA raised $35M on 11/04/2021

Similar Companies

Lucigen

Located in Middleton, WI, Lucigen delivers innovative products and services to life scientists and manufacturers for the most pressing challenges in research and molecular diagnostics. With a focus on quality, ease-of-use, and affordability, Lucigen strives to make our customer’s research, manufacturing and diagnostic testing successful and cost-efficient.

Nutripro Biosystems

Nutripro Biosystems, Inc is a Worthington, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Keros Therapeutics

Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases

Mydecine

Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) is a life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions. Mydecine`s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health, and NeuroPharm focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

Tetracore

At Tetracore, we focus on animal health, domestic preparedness, antibody, clinical, and immunology products. View our products online.